AAPL   397.50 (+3.60%)
FB   247.85 (+1.13%)
GOOGL   1,570.00 (+2.01%)
AMZN   3,328.21 (+4.01%)
GE   6.70 (+0.00%)
TSLA   1,765.05 (+14.27%)
AMD   56.86 (+1.75%)
T   29.92 (-0.70%)
GILD   77.37 (+1.38%)
DIS   119.49 (+0.13%)
NFLX   564.62 (+2.89%)
BAC   24.04 (+0.08%)
BA   175.55 (-1.62%)
AAPL   397.50 (+3.60%)
FB   247.85 (+1.13%)
GOOGL   1,570.00 (+2.01%)
AMZN   3,328.21 (+4.01%)
GE   6.70 (+0.00%)
TSLA   1,765.05 (+14.27%)
AMD   56.86 (+1.75%)
T   29.92 (-0.70%)
GILD   77.37 (+1.38%)
DIS   119.49 (+0.13%)
NFLX   564.62 (+2.89%)
BAC   24.04 (+0.08%)
BA   175.55 (-1.62%)
AAPL   397.50 (+3.60%)
FB   247.85 (+1.13%)
GOOGL   1,570.00 (+2.01%)
AMZN   3,328.21 (+4.01%)
GE   6.70 (+0.00%)
TSLA   1,765.05 (+14.27%)
AMD   56.86 (+1.75%)
T   29.92 (-0.70%)
GILD   77.37 (+1.38%)
DIS   119.49 (+0.13%)
NFLX   564.62 (+2.89%)
BAC   24.04 (+0.08%)
BA   175.55 (-1.62%)
AAPL   397.50 (+3.60%)
FB   247.85 (+1.13%)
GOOGL   1,570.00 (+2.01%)
AMZN   3,328.21 (+4.01%)
GE   6.70 (+0.00%)
TSLA   1,765.05 (+14.27%)
AMD   56.86 (+1.75%)
T   29.92 (-0.70%)
GILD   77.37 (+1.38%)
DIS   119.49 (+0.13%)
NFLX   564.62 (+2.89%)
BAC   24.04 (+0.08%)
BA   175.55 (-1.62%)
Log in

OTCMKTS:EMISEmisphere Technologies Stock Price, Forecast & News

$5.75
+0.07 (+1.23 %)
(As of 07/13/2020 09:03 AM ET)
Add
Compare
Today's Range
$5.57
Now: $5.75
$5.75
50-Day Range
$5.50
MA: $5.63
$5.85
52-Week Range
$3.88
Now: $5.75
$11.23
Volume4,100 shs
Average Volume15,595 shs
Market Capitalization$483.17 million
P/E RatioN/A
Dividend YieldN/A
Beta1.74
Emisphere Technologies, Inc. operates as a commercial stage pharmaceutical and drug delivery company in the United States. The company offers oral Eligen B12 Rx, an oral formulation prescription medical food for use by B12 deficient individuals. It is also developing GLP-1, which is in Phase III clinical trial for the treatment of type 2 diabetes and related conditions. The company's preclinical programs focus on the development of oral formulations for the treatment of diabetes; and products in the areas of cardiovascular, appetite suppression, and pain, as well as in the development and expansion of nutritional supplement products. It has license agreements with Novo Nordisk A/S to develop and commercialize oral formulations of GLP-1 receptor agonists in combination with Emisphere carriers, as well as to develop and commercialize oral formulations of Novo Nordisk's insulin using the company's Eligen Technology. The company was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. Emisphere Technologies, Inc. was founded in 1986 and is based in Roseland, New Jersey.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.72 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:EMIS
CUSIPN/A
Phone973-532-8000

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees6
Market Cap$483.17 million
Next Earnings DateN/A
OptionableNot Optionable

Receive EMIS News and Ratings via Email

Sign-up to receive the latest news and ratings for EMIS and its competitors with MarketBeat's FREE daily newsletter.

Emisphere Technologies (OTCMKTS:EMIS) Frequently Asked Questions

How has Emisphere Technologies' stock been impacted by COVID-19 (Coronavirus)?

Emisphere Technologies' stock was trading at $6.45 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, EMIS shares have decreased by 10.9% and is now trading at $5.75. View which stocks have been most impacted by Coronavirus.

How were Emisphere Technologies' earnings last quarter?

Emisphere Technologies, Inc. (OTCMKTS:EMIS) released its earnings results on Friday, May, 12th. The company reported $0.04 earnings per share (EPS) for the quarter. The company earned $0.22 million during the quarter. View Emisphere Technologies' earnings history.

Has Emisphere Technologies been receiving favorable news coverage?

News stories about EMIS stock have been trending very negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Emisphere Technologies earned a daily sentiment score of -3.2 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news about Emisphere Technologies.

Who are some of Emisphere Technologies' key competitors?

What other stocks do shareholders of Emisphere Technologies own?

Who are Emisphere Technologies' key executives?

Emisphere Technologies' management team includes the following people:
  • Mr. Alan L. Rubino, CEO, Pres & Director (Age 64)
  • Mr. Alan V. Gallantar CPA, Interim Chief Financial Officer (Age 61)

What is Emisphere Technologies' stock symbol?

Emisphere Technologies trades on the OTCMKTS under the ticker symbol "EMIS."

How do I buy shares of Emisphere Technologies?

Shares of EMIS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Emisphere Technologies' stock price today?

One share of EMIS stock can currently be purchased for approximately $5.75.

How big of a company is Emisphere Technologies?

Emisphere Technologies has a market capitalization of $483.17 million. Emisphere Technologies employs 6 workers across the globe.

What is Emisphere Technologies' official website?

The official website for Emisphere Technologies is www.emisphere.com.

How can I contact Emisphere Technologies?

Emisphere Technologies' mailing address is 4 BECKER FARM ROAD SUITE 103, ROSELAND NJ, 07068. The company can be reached via phone at 973-532-8000 or via email at [email protected]

This page was last updated on 7/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.